3D Systems (NYSE:DDD) reported a fourth-quarter loss that underscored the ongoing volatility in the industrial manufacturing sector, even as the company saw a double-digit jump in sequential sales.
Dianthus Therapeutics (NASDAQ:DNTH) is accelerating the development of its lead immunology candidate after an interim analysis of its Phase 3 CAPTIVATE trial yielded positive results earlier than anticipated.
enCore Energy (NASDAQ:EU) reported a surge in operational output for fiscal year 2025 on Monday, as the South Texas-based producer successfully ramped up its Alta Mesa and Rosita projects to capitalize on a tightening global uranium market.
ACCO Brands reported its fourth-quarter and full-year 2025 results on Monday, highlighting a resilient bottom line and expansion in gaming accessories despite a broader slowdown in global demand for traditional office products.
Bristol Myers Squibb reached a major milestone in its next-generation protein degradation program on Monday, reporting that its oral CELMoD agent, mezigdomide, significantly extended the time patients lived without their cancer progressing in a pivotal Phase 3 study.
Pfizer announced positive topline results for its investigational trispecific antibody, tilrekimig, which demonstrated significant skin clearance in adults with moderate to severe eczema and paved the way for a pivotal Phase 3 study later this year.
Korn Ferry (NYSE:KFY) reported a strong third quarter for fiscal 2026, with fee revenue reaching $717.4 million as the global consulting firm successfully leveraged high-growth digital services and long-term contracts to offset broader economic shifts.
ARS Pharmaceuticals reported its 2025 financial results on Monday, highlighting the successful U.S. commercial launch of neffy, the first needle-free epinephrine nasal spray, which now anchors the company’s path toward cash-flow break-even.
Heritage Insurance Holdings (NYSE:HRTG) capped a landmark fiscal year with a surge in fourth-quarter net income, as a dramatically improved combined ratio and strategic geographic expansion propelled book value to record heights.
Signet Jewelers (NYSE:SIG) reported preliminary full-year 2026 results on Monday, revealing that a shift toward higher-end merchandise successfully bolstered annual growth despite a slight cooling in fourth-quarter store traffic.
BETA Technologies reported a significant jump in full-year 2025 revenue following its market debut, as the electric aerospace pioneer scales its charging infrastructure and begins high-volume deliveries of its proprietary propulsion systems.
IDEAYA Biosciences reached a key clinical milestone on Monday, dosing the first patient in its Phase 1 trial for IDE892, a potential best-in-class PRMT5 inhibitor designed to target MTAP-deleted solid tumors.
